Rimegepant interactions

Rimegepant (Nurtec) has 47 documented interactions across the FDA labels and fact sheets we index: 47 major, 0 moderate, 0 minor, and 0 where a label reports no significant interaction. Each entry below quotes the sentence behind it. This drug page is a starting point, not a verdict for your situation.

Major interactions (47)

AmiodaroneantiarrhythmicMajor
• Strong CYP3A4 Inhibitors: Avoid concomitant administration. (Rimegepant label, Drug interactions)
AprepitantCYP3A4 inhibitorMajor
• Strong CYP3A4 Inhibitors: Avoid concomitant administration. (Rimegepant label, Drug interactions)
ArmodafinilCNS stimulantMajor
• Strong and Moderate CYP3A Inducers: Avoid concomitant administration. (Rimegepant label, Drug interactions)
BosentanCYP3A4 inducerMajor
• Strong and Moderate CYP3A Inducers: Avoid concomitant administration. (Rimegepant label, Drug interactions)
CarbamazepineanticonvulsantMajor
• Strong and Moderate CYP3A Inducers: Avoid concomitant administration. (Rimegepant label, Drug interactions)
CenobamateanticonvulsantMajor
• Strong CYP3A4 Inhibitors: Avoid concomitant administration. (Rimegepant label, Drug interactions)
CimetidineH2 blockerMajor
• Strong CYP3A4 Inhibitors: Avoid concomitant administration. (Rimegepant label, Drug interactions)
Clarithromycinmacrolide antibioticMajor
• Strong CYP3A4 Inhibitors: Avoid concomitant administration. (Rimegepant label, Drug interactions)
ClobazambenzodiazepineMajor
• Strong and Moderate CYP3A Inducers: Avoid concomitant administration. (Rimegepant label, Drug interactions)
CyclosporineimmunosuppressantMajor
• Strong CYP3A4 Inhibitors: Avoid concomitant administration. (Rimegepant label, Drug interactions)
Deferasiroxiron supplementMajor
• Strong and Moderate CYP3A Inducers: Avoid concomitant administration. (Rimegepant label, Drug interactions)
DexamethasonecorticosteroidMajor
• Strong and Moderate CYP3A Inducers: Avoid concomitant administration. (Rimegepant label, Drug interactions)
Diltiazemcalcium channel blockerMajor
• Strong CYP3A4 Inhibitors: Avoid concomitant administration. (Rimegepant label, Drug interactions)
DronedaroneantiarrhythmicMajor
• Strong CYP3A4 Inhibitors: Avoid concomitant administration. (Rimegepant label, Drug interactions)
Erythromycinmacrolide antibioticMajor
• Strong CYP3A4 Inhibitors: Avoid concomitant administration. (Rimegepant label, Drug interactions)
EslicarbazepineanticonvulsantMajor
• Strong and Moderate CYP3A Inducers: Avoid concomitant administration. (Rimegepant label, Drug interactions)
EverolimusimmunosuppressantMajor
• Strong CYP3A4 Inhibitors: Avoid concomitant administration. (Rimegepant label, Drug interactions)
FlibanserinCNS depressantMajor
• Potent Inhibitors of P-gp: Avoid another dose of NURTEC ODT within 48 hours when administered with a potent P-gp inhibitor. (Rimegepant label, Drug interactions)
Fluconazoleazole antifungalMajor
• Strong CYP3A4 Inhibitors: Avoid concomitant administration. (Rimegepant label, Drug interactions)
GriseofulvinantifungalMajor
• Strong and Moderate CYP3A Inducers: Avoid concomitant administration. (Rimegepant label, Drug interactions)
ImatinibCYP3A4 inhibitorMajor
• Strong CYP3A4 Inhibitors: Avoid concomitant administration. (Rimegepant label, Drug interactions)
IsoniazidantibioticMajor
• Strong CYP3A4 Inhibitors: Avoid concomitant administration. (Rimegepant label, Drug interactions)
Itraconazoleazole antifungalMajor
• Strong CYP3A4 Inhibitors: Avoid concomitant administration. (Rimegepant label, Drug interactions)
IvacaftorCYP3A4 inhibitorMajor
• Strong CYP3A4 Inhibitors: Avoid concomitant administration. (Rimegepant label, Drug interactions)
Ketoconazoleazole antifungalMajor
• Strong CYP3A4 Inhibitors: Avoid concomitant administration. (Rimegepant label, Drug interactions)
Mirabegronbeta-adrenergic agonistMajor
• Strong CYP3A4 Inhibitors: Avoid concomitant administration. (Rimegepant label, Drug interactions)
ModafinilCNS stimulantMajor
• Strong and Moderate CYP3A Inducers: Avoid concomitant administration. (Rimegepant label, Drug interactions)
Nirmatrelvir and ritonavirantiviralMajor
• Strong CYP3A4 Inhibitors: Avoid concomitant administration. (Rimegepant label, Drug interactions)
OxcarbazepineanticonvulsantMajor
• Strong and Moderate CYP3A Inducers: Avoid concomitant administration. (Rimegepant label, Drug interactions)
PalbociclibCYP3A4 inhibitorMajor
• Strong CYP3A4 Inhibitors: Avoid concomitant administration. (Rimegepant label, Drug interactions)
PerampanelanticonvulsantMajor
• Strong CYP3A4 Inhibitors: Avoid concomitant administration. (Rimegepant label, Drug interactions)
PhenobarbitalbarbiturateMajor
• Strong and Moderate CYP3A Inducers: Avoid concomitant administration. (Rimegepant label, Drug interactions)
Phentermine and topiramateCNS stimulantMajor
• Strong and Moderate CYP3A Inducers: Avoid concomitant administration. (Rimegepant label, Drug interactions)
PhenytoinanticonvulsantMajor
• Strong and Moderate CYP3A Inducers: Avoid concomitant administration. (Rimegepant label, Drug interactions)
Posaconazoleazole antifungalMajor
• Strong CYP3A4 Inhibitors: Avoid concomitant administration. (Rimegepant label, Drug interactions)
PrimidoneanticonvulsantMajor
• Strong and Moderate CYP3A Inducers: Avoid concomitant administration. (Rimegepant label, Drug interactions)
PropafenoneantiarrhythmicMajor
• Potent Inhibitors of P-gp: Avoid another dose of NURTEC ODT within 48 hours when administered with a potent P-gp inhibitor. (Rimegepant label, Drug interactions)
RanolazineQT-prolonging drugMajor
• Strong CYP3A4 Inhibitors: Avoid concomitant administration. (Rimegepant label, Drug interactions)
RifampinantibioticMajor
• Strong and Moderate CYP3A Inducers: Avoid concomitant administration. (Rimegepant label, Drug interactions)
RitonavirantiretroviralMajor
• Strong CYP3A4 Inhibitors: Avoid concomitant administration. (Rimegepant label, Drug interactions)
Sofosbuvir and velpatasvirantiviralMajor
• Potent Inhibitors of P-gp: Avoid another dose of NURTEC ODT within 48 hours when administered with a potent P-gp inhibitor. (Rimegepant label, Drug interactions)
Suvorexantsedative-hypnoticMajor
• Strong CYP3A4 Inhibitors: Avoid concomitant administration. (Rimegepant label, Drug interactions)
Ticagrelorantiplatelet agentMajor
• Strong CYP3A4 Inhibitors: Avoid concomitant administration. (Rimegepant label, Drug interactions)
TopiramateanticonvulsantMajor
• Strong and Moderate CYP3A Inducers: Avoid concomitant administration. (Rimegepant label, Drug interactions)
Verapamilcalcium channel blockerMajor
• Strong CYP3A4 Inhibitors: Avoid concomitant administration. (Rimegepant label, Drug interactions)
Voriconazoleazole antifungalMajor
• Strong CYP3A4 Inhibitors: Avoid concomitant administration. (Rimegepant label, Drug interactions)
ZonisamideanticonvulsantMajor
• Potent Inhibitors of P-gp: Avoid another dose of NURTEC ODT within 48 hours when administered with a potent P-gp inhibitor. (Rimegepant label, Drug interactions)

Check Rimegepant against everything you take. Add your full list; every pair is checked at once.

Open in the checker

Not medical advice. Severity reflects the label's wording, not your circumstances. A "major" flag can be routine under supervision and a "minor" one can matter at high doses. Ask a pharmacist.